Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 33 out of 100. Cognitive tests and assessment

Topic: Risk, prevention and care in population studies

Plain-language summary

The Cronbach alpha coefficient of the RUDAS scale is 0.8529. In our analysis, the scale was found to be highly reliable. In our study, the difference between the RUDAS scale mean scores of the groups was found to be statistically significant (p<0.001). In estimating the Alzheimer's Disease patient group, the AUC value under the curve of the RUDAS score was obtained as 0.998, and the mild cognitive impairment AUC value was obtained as 0.971, which was found to be significant. (p<0.001). The degree of the relationship between the RUDAS scale and the MMSE scale was found to be very strong and statistically significant in the positive direction. (r=0.938 p<0.001) This study showed that the Turkish version of the RUDAS is a valid and reliable scale for the evaluation and follow-up of Alzheimer's disease and mild cognitive impairment in the Turkish population.

What this study adds

Evidence grade: Low

The record lists 87 participants. This study found the Turkish version of the RUDAS scale to be valid and reliable for evaluating Alzheimer's disease and mild cognitive impairment. It is a test-validation study and does not address treatment, cure or prevention.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Gürsoy, G. T., & Kaya, Y. (2025). The Validity and Reliability of the Turkish Version of the Rowland Universal Dementia Assessment Scale (RUDAS) for Alzheimer’s Disease and Mild Cognitive Impairment. Journal of Drug Delivery and Therapeutics. https://doi.org/10.22270/jddt.v15i1.6940

Vancouver

Gürsoy GT, Kaya Y. The Validity and Reliability of the Turkish Version of the Rowland Universal Dementia Assessment Scale (RUDAS) for Alzheimer’s Disease and Mild Cognitive Impairment. Journal of Drug Delivery and Therapeutics. 2025. doi:10.22270/jddt.v15i1.6940.

BibTeX

@article{gursoy2025-682bd5c6,
  author  = {Gürsoy, Görkem Tutal and Kaya, Yıldız},
  title   = {{The Validity and Reliability of the Turkish Version of the Rowland Universal Dementia Assessment Scale (RUDAS) for Alzheimer’s Disease and Mild Cognitive Impairment}},
  journal = {Journal of Drug Delivery and Therapeutics},
  year    = {2025},
  doi     = {10.22270/jddt.v15i1.6940},
  url     = {https://doi.org/10.22270/jddt.v15i1.6940}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

This study found the Turkish version of the RUDAS scale to be valid and reliable for evaluating Alzheimer's disease and mild cognitive impairment. It is a test-validation study and does not address treatment, cure or prevention.

Study details

How this study scored 33/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 0 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 1 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 1 of 7; Citations per year 0 of 5; Impact for its field and year 1 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record 1 of 4; Institution's track record left out, no data; Multicenter collaboration 0 of 3; Indexed in PubMed 1 of 2; Free to read 2 of 2. 32 of the 97 points it could be judged on, which is 33 of 100. Total 33 of 100.32 of the 97 points we could judge = 33 of 100

Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it. We have no data on institution's track record, so that was left out: it earned 32 of the 97 points we could judge it on, which is 33 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Journal of Drug Delivery and Therapeutics)
Journal's citation record 0 / 4 Journal of Drug Delivery and Therapeutics: journal h-index 48 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 1 / 4 87 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 1 / 7 Cited 1 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.3 citations a year over 3 year(s) since 2025
Impact for its field and year 1 / 6 Cited 0.6× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 1 / 4 Last-listed author Yıldız Kaya: h-index 8 (OpenAlex, whole career)
Institution's track record — / 3 No institution listed in OpenAlex — left out of this score
Multicenter collaboration 0 / 3 OpenAlex lists 0 institution(s) in 0 countries — scores zero (affiliation lists can be incomplete)
Indexed in PubMed 1 / 2 Not in PubMed, but has a DOI
Free to read 2 / 2 Free to read
Points 32 / 97 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 32 of the 97 points we could judge it on is 33 out of 100.
Total 33 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Cognitive tests and assessment from nearby years

Also tagged “prevalence”

1,223 studies in the library carry the topic tag “prevalence”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,223 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Cognitive tests and assessment

See all studies in Cognitive tests and assessment →